Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2011

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2011', provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutic pipeline. This report provides information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma). 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Basal Cell Carcinoma (Basal Cell Epithelioma).
• A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview
Therapeutics Development
An Overview of Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma)
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Products under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Infinity Pharmaceuticals, Inc.
Novartis AG
LEO Pharma A/S
Moberg Derma AB
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG3616 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
RG3616 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
IPI-926 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BMS-833923 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PEP005 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
HPPH - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Silicon phthalocyanine 4 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
LDE225 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Imiquimod - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Acitretin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Celecoxib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
API 31510 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Itraconazole - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
LEQ506 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Dz13 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Limtop - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Drug Profile Updates
Basal Cell Carcinoma (Basal Cell Epithelioma) – Product Development Milestones
Basal Cell Carcinoma (Basal Cell Epithelioma) – Product Development Milestones
Featured News & Press Releases
Nov 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop
Nov 09, 2011: Curis Announces FDA Acceptance And Priority Review Of NDA For Vismodegib As Treatment For Advanced Basal Cell Carcinoma
Sep 12, 2011: Genentech Submits New Drug Application To FDA For Vismodegib For Basal Cell Carcinoma
Jun 20, 2011: Roche Reports Positive Results From Phase II Study Of Carcinoma Drug
Mar 21, 2011: Curis Announces Positive Results In Genentech Pivotal Phase II Clinical Trial Of GDC-0449 In Advanced Basal Cell Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2011
Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Infinity Pharmaceuticals, Inc., H2 2011
Novartis AG, H2 2011
LEO Pharma A/S, H2 2011
Moberg Derma AB, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2011
Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top